GC
AGRX

Grimes & Company’s Agile Therapeutics AGRX Stock Holding History

Grimes & Company’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-56
Closed -$23K – 308
2022
Q1 		$23K Buy
56
+14
+33% +$8.94K ﹤0.01% 299
2021
Q4 		$41K Sell
42
-8
-16% -$11.3K ﹤0.01% 297
2021
Q3 		$96K Buy
50
+5
+11% +$11.3K ﹤0.01% 295
2021
Q2 		$121K Buy
45
+19
+73% +$62.6K 0.01% 294
2021
Q1 		$107K Buy
26
+11
+73% +$59.5K 0.01% 272
2020
Q4 		$86K Hold
15
– – ﹤0.01% 260
2020
Q3 		$89K Buy
15
+4
+36% +$22.9K 0.01% 243
2020
Q2 		$59K Buy
11
+1
+10% +$5.2K ﹤0.01% 242
2020
Q1 		$37K Hold
10
– – ﹤0.01% 225
2019
Q4 		$50K Buy
+10
New +$34.9K ﹤0.01% 263

Other funds holding AGRX

PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $93.1B AUM 61.18% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Citigroup
Citigroup New York $157B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $77.3B AUM 36.07% 1-Year Est. Return